Page 147 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

References
1. Vanderbilt-University. Calculations of the number of adverse events prevented with an effective preemptive genotyping program. 2017; http://data.vanderbilt.edu/rapache/Case4PG Accessed 20 November 2017.
2. Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639- 4 1650.
3. Terrazzino S, Cargnin S, Del RM, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta- analysis. Pharmacogenomics. 2013;14(11):1255-1272.
4. Rosmarin D, Palles C, Pagnamenta A, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut. 2015;64(1):111-120.
5. EMA. European Medicines Agency. [Capecitabine (Xeloda)] Summary of Product Characteristics. 2008; www.ema.europa.eu. Accessed November 14th, 2017.
6. FDA. US Food and Drug Administration. Prescribing information Xeloda. http://www.fda.gov. Accessed November 14th 2017.
7. CBG-MEB. Dutch Medicines Evaluation Board. SPC Fluorouracil Accord 50mg/ml. http://www. cbg-meb.nl. Accessed November 14th 2017.
8. FDA. US Food and Drug Administration. Prescribing information fluorouracil Teva Pharms USA. http://www.fda.gov Accessed November 14th 2017.
Supplement
145